| Status: Under consideration by AWMSG Scrutiny Panel | |
In combination with FOLFOX or FOLFIRI for off-label first line treatment of BRAF (V600E) mutated metastatic colorectal cancer. |
|
Medicine details |
|
| Medicine name | cetuximab + encorafenib |
| Formulation | capsules (encorafenib), solution for infusion (cetuximab) |
| Reference number | 6960 |
| Indication | As above |
| Company | Pierre Fabry Ltd (encorafenib), Merck Serono Ltd (cetuximab) |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 11/09/2025 |